Jah Yeon Choi1, Cheol Ung Choi2, Byoung Geol Choi1, Yoonjee Park1, Dong Oh Kang1, Won Young Jang3, Woohyeun Kim1, Jin Oh Na1, Jin Won Kim1, Eung Ju Kim1, Seung-Woon Rha1, Chang Gyu Park1, Hong Seog Seo1, Myung Ho Jeong4, Sung-Chull Chae5, In-Whan Seong6, Chang-Hwan Yoon7, Kwang Soo Cha8, Seok Kyu Oh9. 1. Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul, 152-703, Republic of Korea. 2. Cardiovascular Center, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul, 152-703, Republic of Korea. wmagpie@korea.com. 3. Cardiovascular Center, Catholic University of Korea St. Vincent Hospital, Suwon, Republic of Korea. 4. Chonnam National University Hospital, Gwangju, Republic of Korea. 5. Kyungbook National University Hospital, Kyungbook National University School of Medicine, Daegu, Republic of Korea. 6. Chungnam National University Hospital, Daejeon, Republic of Korea. 7. Seoul National University Bundang Hospital, Seongnam, South Korea. 8. Pusan National University Hospital, Busan, South Korea. 9. Wonkwang University School of Medicine, Iksan, Korea.
Abstract
BACKGROUND: High-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. However, there have been consistent concerns regarding its association with diabetes mellitus. We investigated the effect of high-intensity atorvastatin and rosuvastatin on new-onset diabetes mellitus (NODM) and cardiovascular outcomes over a 3-year follow-up period. METHODS: Data from the Korea Acute Myocardial Infarction Registry were collected from November 2011 to October 2015, and 13,104 patients with AMI were enrolled from major cardiovascular centers. Among them, 2221 patients without diabetes who had been administered with high-intensity atorvastatin (40-80 mg) and rosuvastatin (20 mg) were investigated. The atorvastatin and rosuvastatin groups were evaluated for the incidence of NODM and major adverse cardiac events (MACE) including death, myocardial infarction, and revascularization cases in the following 3 years. RESULTS: Baseline characteristics were comparable between the two groups. Event-free survival rate of NODM was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value = 0.550). The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. 89.6%, respectively; Log rank P-value = 0.662). Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE. CONCLUSIONS: Administering high-intensity atorvastatin and rosuvastatin in patients with AMI produced comparable effects on NODM and clinical outcomes, suggesting their clinical equivalence in secondary prevention.
BACKGROUND: High-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. However, there have been consistent concerns regarding its association with diabetes mellitus. We investigated the effect of high-intensity atorvastatin and rosuvastatin on new-onset diabetes mellitus (NODM) and cardiovascular outcomes over a 3-year follow-up period. METHODS: Data from the Korea Acute Myocardial Infarction Registry were collected from November 2011 to October 2015, and 13,104 patients with AMI were enrolled from major cardiovascular centers. Among them, 2221 patients without diabetes who had been administered with high-intensity atorvastatin (40-80 mg) and rosuvastatin (20 mg) were investigated. The atorvastatin and rosuvastatin groups were evaluated for the incidence of NODM and major adverse cardiac events (MACE) including death, myocardial infarction, and revascularization cases in the following 3 years. RESULTS: Baseline characteristics were comparable between the two groups. Event-free survival rate of NODM was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value = 0.550). The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. 89.6%, respectively; Log rank P-value = 0.662). Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE. CONCLUSIONS: Administering high-intensity atorvastatin and rosuvastatin in patients with AMI produced comparable effects on NODM and clinical outcomes, suggesting their clinical equivalence in secondary prevention.
Authors: Jah Yeon Choi; Cheol Ung Choi; Soon-Young Hwang; Byoung Geol Choi; Won Young Jang; Do Young Kim; Woohyeun Kim; Eun Jin Park; Sunki Lee; Jin Oh Na; Jin Won Kim; Eung Ju Kim; Seung-Woon Rha; Chang Gyu Park; Hong Seog Seo; Sung-Chull Chae; Young Jo Kim; Myeong Chan Cho; Chong Jin Kim; Hyo-Soo Kim; Myung Ho Jeong Journal: Am J Cardiol Date: 2018-06-27 Impact factor: 2.778
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: J Am Coll Cardiol Date: 2018-11-10 Impact factor: 24.094
Authors: David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray Journal: JAMA Date: 2011-06-22 Impact factor: 56.272
Authors: Robert A Scott; Nicholas J Wareham; Luca A Lotta; Stephen J Sharp; Stephen Burgess; John R B Perry; Isobel D Stewart; Sara M Willems; Jian'an Luan; Eva Ardanaz; Larraitz Arriola; Beverley Balkau; Heiner Boeing; Panos Deloukas; Nita G Forouhi; Paul W Franks; Sara Grioni; Rudolf Kaaks; Timothy J Key; Carmen Navarro; Peter M Nilsson; Kim Overvad; Domenico Palli; Salvatore Panico; Jose-Ramón Quirós; Elio Riboli; Olov Rolandsson; Carlotta Sacerdote; Elena C Salamanca; Nadia Slimani; Annemieke Mw Spijkerman; Anne Tjonneland; Rosario Tumino; Daphne L van der A; Yvonne T van der Schouw; Mark I McCarthy; Inês Barroso; Stephen O'Rahilly; David B Savage; Naveed Sattar; Claudia Langenberg Journal: JAMA Date: 2016-10-04 Impact factor: 56.272
Authors: Dominika Nowis; Agata Malenda; Karolina Furs; Bozenna Oleszczak; Radoslaw Sadowski; Justyna Chlebowska; Malgorzata Firczuk; Janusz M Bujnicki; Adam D Staruch; Radoslaw Zagozdzon; Eliza Glodkowska-Mrowka; Leszek Szablewski; Jakub Golab Journal: BMJ Open Diabetes Res Care Date: 2014-04-26
Authors: Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine Journal: N Engl J Med Date: 2016-12-01 Impact factor: 91.245